|
|
675 Almanor Ave C/O The Parkinsons Institute
Sunnyvale, CA 94085 USA
phone:(408) 737-2734
fax:(408) 852-4427
|
|
| Symbol |
AMBS |
| Exchange |
OTC BB |
| Founded |
2008 |
| Employees |
3 |
|
|
| www.amarantustherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biotechnology company that develops modifying treatments to address cell death. |
|
| Management |
| Gerald E. Commissiong, President and Chief Executive Officer; John W. Commissiong, PhD, Chief Scientific Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| Parkinsons Disease, PD, CNS, cell death, biotechnology, apoptosis, neurodegenerative diseases, cardiovascular diseases, cardiovascular, neurodegenerative, Parkinsons disease, Myocardial Infaraction |
|
|
|
|
|
|
| Description |
|
Amarantus Biosciences Pioneering the development of a novel therapeutic protein that has neuron-protective properties - termed MANF - which has the potential to serve as a first-in-class treatment for neurological disorders that stops and/or reverses their debilitating effects. Importantly, MANF is also significantly cardiac-protective, providing Amarantus the ability to employ a two pronged drug development approach - a neurological disorder platform, and a heart disease platform. View the OneMedPlace Initiation Report of Amarantus. |
|
| Products / Services |
|
The most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinsons Disease and Myocardial Infarction. Parkinsons Disease generates over $2B in sales annually, and ...
view more
|
|
| Technology / Differentiation |
Discovered from Amarantus proprietary Discovery Engine for Secreted Proteins (DESP), AMRS001, also known as MANF, is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of Parkinsons disease. Coming after other selective neurotrophic factors such as GDNF, Neurturin, NGF, and others, the AMRS001 discovery protocols were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra.
While the clinical efficacy and benefit of neurotrophic factors has been in doubt, AMRS001 represents a new family of neurotrophic factors with mechanisms of action fundamentally differentiated from its predecessors.
AMRS001 is an endogenous, widely expressed and highly potent growth factor involved in the prevention of apoptosis. This type of cell death is associated with several devastating human diseases as well as injury related disorders. By inhibiting certain pro-apoptotic caspase enzymes , AMRS001 is highly indicated for the treatment of several poorly served medical markets, including PD and Myocardial Infarction. |
|
|
| Strategy |
Amarantus business strategy, is to discover clinically relevant secreted human proteins, each with the potential to address several critically important medical indications, using our Discovery Engine for Secreted Proteins and develop them in order to address significant patient needs.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
